Bristol Myers Squibb Chooses Houston for $2.3B Investment

Bristol Myers Squibb (BMS) selected Houston as the site for a new, multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.

The selection of Houston marks a significant milestone in BMS’ $40 billion commitment to invest in the United States over five years across research and development, technology and domestic manufacturing.

The Houston campus will be modular and multi-modal. Its modular design allows BMS to add and reconfigure manufacturing capacity as needed, reflecting BMS’ current and future pipeline. Its multi-modal capabilities allow BMS to manufacture multiple types of medicines – such as small molecules, biologics, and antibody-drug conjugates – across a range of disease areas.

Last year, Eli Lilly announced it would invest in a $6.5 billion active pharmaceutical ingredients plant, also in the Generation Park complex in Houston.

Join the region’s leading multifamily owners, developers, investors, lenders, and brokers at Connect Texas Multifamily on August 13 in Dallas for a focused discussion on the market forces redefining Texas real estate. Be in the room with the decision-makers driving deals and growth across Texas. Register today: www.ConnectTXMF2026.com.